Supplier of cellular orchestration solutions TrakCel and healthcare company AmerisourceBergen have expanded their platform capabilities to provide physicians and patient services teams more visibility across the treatment development and patient journey.
TrakCel in 2022 completed the first phase of integrating its next-generation cellular orchestration platform, OCELLOS, with AmerisourceBergen’s Fusion, a customer relationship management and patient support ecosystem. The initial integration allowed physicians to receive a near real-time response on a patient’s coverage determination after creating a patient account and entering enrolment information - all within a single portal experience.
The newest features will provide physicians and case managers with significantly more insight into the progression of the treatment, with the enhanced integration available with the OCELLOS 4.0.
Ravi Nalliah, TrakCel’s Chief Product and Strategy Officer, said: “The ongoing commercialisation of cell and gene therapies is happening today. Technological development has outpaced the ability to supply these therapies to patients.”
This collaboration with TrakCel means we can improve speed-to-therapy and simplify the care coordination process
He continued: “This integration will ensure that all those involved in the supply and value chains of cell and gene therapies will be able to be kept up to the minute about the progression of a therapy as well as reimbursement and benefit eligibility, allowing them to schedule treatments and appointments more effectively and sympathetically to keep patients better informed.”
The TrakCel and AmerisourceBergen integration is designed to facilitate heightened care coordination across the patient journey to provide an enhanced patient and caregiver experience.
Dale Hanna, Director of Cell and Gene Therapy Solutions at AmerisourceBergen, said: “Whether it’s introducing new solutions or collaborating with partners across the supply chain, we are focused on reducing the challenges across the commercialisation and treatment journey.”
He continued: “This collaboration with TrakCel means we can improve speed-to-therapy and simplify the care coordination process.”
The data exchange interface that OCELLOS uses has been enhanced to achieve this greater level of sharing in OCELLOS 4.0 and this will also benefit other types of integration and supply chain partners of various types of couriers to CMOs and therapy developer’s own in-house systems.
Launched by TrakCel in 2021, the OCELLOS platform has moved the company away from custom-written code which takes more time to alter, develop and maintain.
